433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

• Min Yi,
• Celeste Lebbe,
• Parminder Singh,
• Omid Hamid,
• Jason Chesney,
• Igor Puzanov,
• Mohammed Milhem,
• Merrick Ross,
• Janice Mehnert,
• Theodore Logan,
• Philip Friedlander,
• Frances Collichio,
• Claus Garbe,
• John Glaspy,
• Axel Hauschild,
• Wendy Snyder

Affiliations

Min Yi

1 Department of Epidemiology, School of Public Health, Nantong University, Nantong, China

Celeste Lebbe

3 Service de Dermatologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Paris, France

Parminder Singh

Medicine, Imperial College London, London, UK

Omid Hamid

6Angeles Clinic and Research Institute, Los Angeles, CA, USA

Jason Chesney

Aff5 grid.266623.50000000121131622University of Louisville Louisville KY USA

Igor Puzanov

9Roswell Park Cancer Institute, Buffalo, NY, USA

Mohammed Milhem

Aff10 grid.214572.70000000419368294University of Iowa Iowa City IA USA

Merrick Ross

Aff6 grid.240145.60000000122914776MD Anderson Cancer Center Houston TX USA

Janice Mehnert

6Perlmutter Cancer Center at NYU Langone, New York, NY, USA

Theodore Logan

Aff33 grid.411377.7000000010790959XSimon Cancer CenterIndiana University Indianapolis IN USA

Philip Friedlander

Aff222 grid.59734.3c0000000106702351Icahn School of Medicine at Mount Sinai New York NY USA

Frances Collichio

Aff2 0000 0001 1034 1720grid.410711.2University of North Carolina Medical Center Chapel Hill NC USA

Claus Garbe

Aff1 0000 0001 0196 8249grid.411544.1Center for Dermatooncology, Department of DermatologyUniversity Hospital Tuebingen Liebermeisterstr. 25 72076 Tuebingen Germany

John Glaspy

Aff5 grid.19006.3e0000000096326718UCLA Jonsson Comprehesive Cancer Center Los Angeles CA USA

Axel Hauschild

11 Department of Dermatology, University Hospital (UKSH), Kiel, Germany

Wendy Snyder

14Amgen Inc., Thousand Oaks, CA, USA